These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8640226)

  • 1. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.
    Ikeda H; Yamaguchi M; Sugai S; Aze Y; Narumiya S; Kakizuka A
    Nat Genet; 1996 Jun; 13(2):196-202. PubMed ID: 8640226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.
    Cemal CK; Carroll CJ; Lawrence L; Lowrie MB; Ruddle P; Al-Mahdawi S; King RH; Pook MA; Huxley C; Chamberlain S
    Hum Mol Genet; 2002 May; 11(9):1075-94. PubMed ID: 11978767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.
    Nishiyama K; Murayama S; Goto J; Watanabe M; Hashida H; Katayama S; Nomura Y; Nakamura S; Kanazawa I
    Ann Neurol; 1996 Nov; 40(5):776-81. PubMed ID: 8957019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
    Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
    J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
    Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
    Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single sperm analysis of the CAG repeats in the gene for Machado-Joseph disease (MJD1): evidence for non-Mendelian transmission of the MJD1 gene and for the effect of the intragenic CGG/GGG polymorphism on the intergenerational instability.
    Takiyama Y; Sakoe K; Soutome M; Namekawa M; Ogawa T; Nakano I; Igarashi S; Oyake M; Tanaka H; Tsuji S; Nishizawa M
    Hum Mol Genet; 1997 Jul; 6(7):1063-8. PubMed ID: 9215676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.
    Chou AH; Yeh TH; Ouyang P; Chen YL; Chen SY; Wang HL
    Neurobiol Dis; 2008 Jul; 31(1):89-101. PubMed ID: 18502140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential susceptibility of cultured cell lines to aggregate formation and cell death produced by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
    Yoshizawa T; Yoshida H; Shoji S
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):349-52. PubMed ID: 11719271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
    Griffin JL; Cemal CK; Pook MA
    Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compromised mitochondrial complex II in models of Machado-Joseph disease.
    Laço MN; Oliveira CR; Paulson HL; Rego AC
    Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
    Tsai HF; Tsai HJ; Hsieh M
    Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of the unstable expanded CAG repeat in the MJD1 gene in four Brazilian families of Portuguese descent with Machado-Joseph disease.
    Stevanin G; Cassa E; Cancel G; Abbas N; Dürr A; Jardim E; Agid Y; Sousa PS; Brice A
    J Med Genet; 1995 Oct; 32(10):827-30. PubMed ID: 8558567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila).
    Kim YT; Shin SM; Lee WY; Kim GM; Jin DK
    Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
    Yoshizawa T; Yamagishi Y; Koseki N; Goto J; Yoshida H; Shibasaki F; Shoji S; Kanazawa I
    Hum Mol Genet; 2000 Jan; 9(1):69-78. PubMed ID: 10587580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of three intragenic polymorphisms in the Machado-Joseph disease gene (MJD1) in relation to genetic instability of the (CAG)n tract.
    Maciel P; Gaspar C; Guimarães L; Goto J; Lopes-Cendes I; Hayes S; Arvidsson K; Dias A; Sequeiros J; Sousa A; Rouleau GA
    Eur J Hum Genet; 1999; 7(2):147-56. PubMed ID: 10196697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain.
    Paulson HL; Das SS; Crino PB; Perez MK; Patel SC; Gotsdiner D; Fischbeck KH; Pittman RN
    Ann Neurol; 1997 Apr; 41(4):453-62. PubMed ID: 9124802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CREB-binding protein sequestration by expanded polyglutamine.
    McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
    Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
    Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
    J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms to control degradation of polyglutamine-containing protein].
    Nakayama K
    Rinsho Shinkeigaku; 2003 Nov; 43(11):906-8. PubMed ID: 15152500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.